Jeffrey A. Hubbell

This paper develops a nanotherapy to reprogram antigen-presenting cells and induce T cell anergy, delaying type 1 diabetes onset in mice.

This study shows that albumin-fused IL-10 reduces experimental autoimmune encephalomyelitis by enhancing immunoregulation in secondary lymphoid organs.

This paper develops a composite biomaterial combining polyelectrolyte complex micelles with hyaluronic acid gels to deliver miR-92a inhibitors, enhancing angiogenesis and accelerating wound healing in diabetic mice.

This study shows that membrane-localized xenoantigens enhance CD4+ T cell responses and improve anti-PD-1 therapy efficacy in pre-immunized mice, using OVA and VZV gE antigens.

This paper develops a targeted IL-10 therapy by fusing it with an LDL-binding antibody fragment, showing reduced vascular inflammation in atherosclerotic mice.

This paper develops a zwitterionic hydrogel-based double-network design for PEDOT:PSS that suppresses the foreign body response by 64% and improves conductivity by over one order of magnitude.

This study shows that an extracellular matrix coating similar to articular cartilage reduces myofibroblast differentiation and fibrosis in both in vitro and in vivo models.

This paper develops a modular nanoparticle platform for targeted mRNA delivery to inflamed endothelial cells, showing efficacy in treating ARDS and atherosclerosis by restoring disease-related gene pathways.

This study develops butyrate-prodrug micelles that target lymphatics to induce long-term immune modulation and reduce arthritis in mice.

The paper describes a method using engineered Flt3L to induce a tolerogenic immune state, reducing anti-drug antibodies to a fungal enzyme.